Hub : Traits :

Crohns Disease (2017)

1082 significantly associated models · 253 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 7314655 8738937 1 1 2.3e-08 7.4e-08 3.8e-06 26 PARK7
2 1 66304567 68152438 2 2 6.6e-16 5.8e-97 5.3e-81 17 MIER1 SGIP1
3 1 113751640 115152814 1 1 1.1e-08 6.4e-16 1.6e-09 44 DCLRE1B
4 1 154325302 156572984 16 1 2.5e-11 6.8e-09 4.0e-01 98 ADAM15
5 1 160107588 161512731 1 1 1.9e-07 3.7e-08 1.0e+00 100 CD244
6 2 24324172 25837917 3 1 1.0e-13 2.6e-11 8.8e-01 100 ADCY3
7 2 26883355 29344127 2 2 5.2e-12 6.3e-11 9.7e-01 100 AC074117.10 RP11-373D23.3
8 2 42753863 44157441 2 1 4.0e-09 1.5e-11 9.2e-05 66 AC010883.5
9 2 60466491 62107632 5 1 3.5e-12 5.9e-14 7.9e-04 80 AC010733.5
10 2 101981794 103767612 4 2 7.3e-13 1.6e-13 1.0e+00 100 IL18R1 IL1RL1
11 2 197976089 200117777 1 1 5.9e-08 5.0e-08 1.5e-01 93 PLCL1
12 2 230396934 231875433 1 1 1.0e-07 2.8e-14 1.4e-08 44 SP140
13 2 233227833 235170697 4 2 5.4e-61 1.8e-62 1.0e+00 100 ATG16L1
14 3 47911521 50921261 23 1 4.9e-26 4.6e-24 3.4e-02 96 MST1
15 3 52242902 53860103 4 1 4.6e-09 7.9e-09 3.0e-01 97 RFT1
16 3 140350567 141867638 1 1 1.1e-07 3.1e-08 1.0e+00 100 ZBTB38
17 4 122377715 123976639 1 1 3.6e-08 2.4e-08 1.7e-01 94 KIAA1109
18 5 39986432 41555158 4 5 2.7e-22 8.3e-56 2.7e-17 71 CARD6 PRKAA1 PTGER4
19 5 95519506 97065386 3 1 4.7e-15 5.1e-15 1.0e+00 100 ERAP2
20 5 129797129 132900729 19 9 1.1e-33 5.6e-36 NaN NaN ANKRD43 HINT1 P4HA2 PDLIM4 SLC22A5 UQCRQ
21 5 140789933 142230251 1 1 1.5e-12 4.1e-12 3.4e-01 98 NDFIP1
22 5 149390148 151236214 6 1 9.1e-20 2.1e-20 3.0e-02 94 ZNF300P1
23 5 158044539 159448136 1 1 1.7e-07 7.5e-22 4.9e-16 29 IL12B
24 6 126752798 128214882 1 1 1.8e-07 1.8e-09 2.4e-03 74 RSPO3
25 6 166651581 167841508 4 1 4.5e-23 3.7e-22 3.1e-02 95 RNASET2
26 7 99591418 100979310 1 1 4.6e-08 5.0e-06 8.4e-02 86 GIGYF1
27 9 108998 1162143 2 1 2.8e-07 6.0e-07 6.6e-01 99 DOCK8
28 9 4287179 5824205 2 1 3.7e-14 1.6e-16 1.0e-03 84 IGHEP2
29 9 116849447 118389134 2 2 4.3e-21 1.8e-21 4.6e-02 96 TNFSF15 TNFSF8
30 9 138525778 140321666 9 3 1.2e-28 3.1e-30 1.0e+00 100 CARD9 RP11-611D20.2
31 10 30028267 31432776 1 1 4.1e-08 1.9e-11 2.2e-05 60 MAP3K8
32 10 34607015 36198981 3 1 1.4e-14 6.3e-15 1.0e+00 100 RP11-297A16.2
33 10 63856856 65264300 2 1 1.7e-17 5.5e-29 3.9e-14 54 ADO
34 10 74714177 76323150 11 1 1.8e-11 6.0e-11 3.4e-03 80 RP11-464F9.22
35 10 80130592 82984432 2 2 5.3e-15 8.9e-15 3.0e-05 71 TSPAN14 ZMIZ1
36 11 63316786 64820283 2 1 1.9e-08 3.2e-07 2.2e-01 94 PPP1R14B
37 11 64954053 66333072 1 1 2.0e-07 2.0e-06 1.0e-02 71 FIBP
38 11 75457950 77069746 2 2 1.1e-13 4.7e-24 1.9e-10 60 C11orf30 LRRC32
39 12 39904158 41454590 1 2 2.8e-11 6.1e-21 3.6e-09 60 LRRK2
40 13 43756650 45157394 1 1 3.3e-12 1.4e-13 1.0e+00 100 LACC1
41 14 87606646 89154624 1 1 1.0e-08 2.0e-12 7.2e-08 41 GALC
42 14 103161201 104666821 1 1 4.1e-07 4.1e-07 1.0e+00 100 MARK3
43 15 66662107 68183665 1 1 8.4e-12 2.4e-19 4.8e-09 58 SMAD3
44 16 10646170 12426645 2 1 8.4e-11 2.8e-08 9.2e-02 91 RMI2
45 16 27655848 30141258 27 1 9.6e-15 6.9e-13 2.8e-01 98 NFATC2IP
46 16 49403920 51535063 8 16 4.8e-71 1.8e-108 NaN NaN ADCY7 CYLD HEATR3 NKD1 NOD2 RP11-429P3.3
47 17 25295032 26643541 1 1 4.3e-08 1.5e-09 5.2e-03 79 KSR1
48 17 36710513 39048774 13 1 3.7e-19 5.1e-19 1.3e-02 92 PNMT
49 17 39328012 41699963 8 2 3.8e-12 1.8e-12 2.0e-02 89 NAGLU PTRF
50 19 388413 1802433 2 1 5.1e-16 9.1e-21 4.2e-10 55 POLR2E
51 19 9829303 11376675 2 2 3.7e-10 2.8e-13 9.4e-11 21 CDKN2D PDE4A
52 19 46157004 47589895 1 1 4.6e-08 3.6e-07 1.0e+00 100 PPP5C
53 19 48464978 49935001 3 2 1.5e-10 2.3e-11 3.3e-01 98 FUT2
54 19 58389355 59095126 1 1 1.4e-07 4.6e-06 4.7e-02 81 RPL23AP79
55 20 43825556 45456440 2 2 6.1e-09 1.3e-09 1.0e+00 100 CD40 NEURL2
56 20 61522825 62912463 10 2 2.9e-15 2.7e-13 1.0e+00 100 LIME1 STMN3
57 21 15634304 17135372 1 1 1.3e-08 2.7e-27 2.2e-20 27 NRIP1
58 21 34077531 35561665 2 2 2.4e-07 1.1e-14 1.8e-03 84 DNAJC28 IFNGR2
59 21 44948764 46443886 2 2 1.1e-08 2.0e-19 4.0e-11 46 ICOSLG PFKL
60 22 21053389 22685340 5 1 9.6e-16 6.3e-16 1.0e+00 100 CCDC116
61 22 29585080 31118395 1 1 1.8e-07 4.2e-07 7.6e-03 72 MTMR3
62 22 36500899 37910395 1 1 5.0e-09 1.8e-08 1.0e+00 100 PVALB
63 22 38719189 40529415 3 2 1.1e-15 7.7e-21 8.8e-09 62 APOBEC3D SYNGR1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Irritable Bowel Disease (IBD) 18.21 76 60 181.8 0.98 1.7e-62 AC010733.5 AC010883.5 AC074117.10 ADAM15 ADCY3 ADCY7 ADO ANKRD43 APOBEC3D ATG16L1 C11orf30 CARD6 CARD9 CCDC116 CD244 CD40 CDKN2D CYLD DOCK8 ERAP2 FIBP FUT2 GALC GIGYF1 HEATR3 HINT1 ICOSLG IGHEP2 IL12B IL18R1 IL1RL1 KIAA1109 LACC1 LIME1 LRRC32 LRRK2 MAP3K8 MARK3 MIER1 MST1 MTMR3 NAGLU NDFIP1 NFATC2IP NKD1 NOD2 NRIP1 P4HA2 PARK7 PDE4A PDLIM4 PFKL PNMT POLR2E PPP1R14B PPP5C PTGER4 PTRF RMI2 RNASET2 RP11-297A16.2 RP11-373D23.3 RP11-464F9.22 RP11-611D20.2 RPL23AP79 SGIP1 SLC22A5 SMAD3 SP140 STMN3 SYNGR1 TNFSF15 TSPAN14 UQCRQ ZMIZ1 ZNF300P1
Ulcerative Colitis (UC) 6.55 28 12 36.4 0.97 7.1e-18 AC010733.5 ADO C11orf30 CARD6 CARD9 CCDC116 ICOSLG IGHEP2 IL12B KIAA1109 LIME1 LRRC32 MST1 NAGLU NFATC2IP NRIP1 PARK7 PDE4A PFKL PNMT PTRF RP11-611D20.2 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15 ZNF300P1
Reaction Time 0.93 1 0 0.0 0.00 1.0e+00 ADCY3
Verbal and Numeric Reasoning (VNR) 1.18 3 2 6.1 0.00 1.0e+00 ADCY3 MST1 NFATC2IP
Breast Cancer 1.86 6 5 15.2 0.36 3.9e-01 ADCY3 DCLRE1B PARK7 SLC22A5 UQCRQ ZBTB38
Prostate Cancer 1.56 3 1 3.0 0.00 1.0e+00 C11orf30 LIME1 PRKAA1
Age at First Birth 0.92 1 0 0.0 0.00 1.0e+00 MST1
Body Mass Index (BMI) (2010) 1.37 2 2 6.1 0.00 1.0e+00 ADCY3 NFATC2IP
Crohns Disease (2012) 18.95 58 36 109.1 -0.99 9.6e-70 AC010733.5 ADAM15 ADCY3 ADCY7 ADO APOBEC3D ATG16L1 CARD6 CCDC116 CYLD ERAP2 FUT2 GALC HINT1 ICOSLG IGHEP2 IL12B IL18R1 IL1RL1 LACC1 LIME1 LRRC32 LRRK2 MIER1 MST1 NAGLU NDFIP1 NFATC2IP NKD1 NOD2 P4HA2 PDE4A PDLIM4 PFKL PLCL1 PNMT PPP1R14B PRKAA1 PTGER4 PTRF RFT1 RMI2 RNASET2 RP11-297A16.2 RP11-373D23.3 RP11-464F9.22 RPL23AP79 RSPO3 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15 TNFSF8 TSPAN14 UQCRQ ZMIZ1 ZNF300P1
Fasting Glucose 2.02 2 1 3.0 0.00 1.0e+00 AC074117.10 RP11-373D23.3
HDL Cholesterol 1.57 3 2 6.1 0.00 1.0e+00 CCDC116 PNMT RSPO3
LDL Cholesterol 1.07 1 0 0.0 0.00 1.0e+00 FUT2
Lupus 1.99 3 1 3.0 0.00 1.0e+00 CCDC116 DCLRE1B FUT2
Primary Biliary Cirrhosis 2.21 4 3 9.1 -1.00 1.9e-03 PNMT PPP1R14B RMI2 SYNGR1
Rheumatoid Arthritis 3.03 3 2 6.1 0.00 1.0e+00 CD40 DCLRE1B PNMT
Schizophrenia 1.08 3 1 3.0 0.00 1.0e+00 GIGYF1 LACC1 PLCL1
Triglycerides 4.00 4 2 6.1 -0.18 8.2e-01 AC074117.10 NEURL2 RP11-373D23.3 RSPO3
Ulcerative Colitis 5.43 14 7 21.2 -0.98 2.0e-10 AC010733.5 CARD9 IGHEP2 LIME1 LRRK2 MST1 PARK7 PNMT PTRF RP11-297A16.2 SLC22A5 STMN3 SYNGR1 TNFSF15
Blood Eosinophil Count 8.25 29 23 69.7 0.28 1.2e-01 AC010883.5 ADCY3 ADO ANKRD43 C11orf30 CARD9 CCDC116 ERAP2 GIGYF1 HINT1 ICOSLG IGHEP2 IL1RL1 KIAA1109 LRRC32 MARK3 NDFIP1 P4HA2 PDLIM4 PFKL PPP5C PVALB RFT1 RP11-297A16.2 SLC22A5 SMAD3 TNFSF15 TNFSF8 UQCRQ
Blood Platelet Count 2.77 32 23 69.7 0.31 4.6e-02 AC010883.5 AC074117.10 ADCY7 ADO ANKRD43 ATG16L1 C11orf30 DOCK8 FUT2 HEATR3 HINT1 IGHEP2 LIME1 MARK3 MST1 MTMR3 NDFIP1 P4HA2 PDLIM4 PNMT PPP1R14B PTGER4 RMI2 RP11-373D23.3 RP11-429P3.3 RP11-464F9.22 RPL23AP79 RSPO3 SLC22A5 STMN3 UQCRQ ZMIZ1
Blood Red Count 1.34 17 10 30.3 -0.19 4.7e-01 DOCK8 GIGYF1 IGHEP2 LIME1 MST1 NDFIP1 NEURL2 NFATC2IP PLCL1 PNMT POLR2E PPP5C PTGER4 RP11-373D23.3 RSPO3 STMN3 ZBTB38
Blood White Count 4.20 28 23 69.7 0.15 3.9e-01 AC010733.5 AC074117.10 ADCY3 ADCY7 ADO ANKRD43 CARD9 CCDC116 CDKN2D DCLRE1B ERAP2 HEATR3 HINT1 LIME1 NDFIP1 P4HA2 PDE4A PDLIM4 PNMT POLR2E RFT1 RNASET2 RP11-373D23.3 RP11-429P3.3 SLC22A5 STMN3 TSPAN14 UQCRQ
Heel T-Score 3.34 13 9 27.3 -0.03 9.1e-01 AC010883.5 CCDC116 DOCK8 LIME1 MARK3 MST1 NEURL2 PPP1R14B RFT1 RPL23AP79 RSPO3 TSPAN14 ZBTB38
BMI 1.62 11 6 18.2 -0.51 1.1e-01 ADCY3 FIBP GALC HINT1 LIME1 MARK3 MST1 NFATC2IP PLCL1 PPP1R14B RFT1
Height 3.18 27 24 72.7 -0.45 1.0e-02 AC010883.5 AC074117.10 ADCY3 ADO ANKRD43 APOBEC3D ATG16L1 C11orf30 CARD9 CCDC116 FUT2 HINT1 IL18R1 LIME1 MARK3 MIER1 P4HA2 PARK7 PDE4A PDLIM4 PTRF RFT1 RP11-373D23.3 RSPO3 SLC22A5 UQCRQ ZBTB38
Waist Hip Ratio (WHR) 1.52 5 2 6.1 -0.52 3.7e-01 AC010883.5 FUT2 PPP1R14B RSPO3 ZBTB38
Systolic Blood Pressure 1.25 14 8 24.2 -0.05 8.6e-01 AC074117.10 ADCY3 ADO C11orf30 CCDC116 DOCK8 ERAP2 FUT2 PRKAA1 RP11-297A16.2 RP11-464F9.22 SMAD3 STMN3 TSPAN14
Smoking Status 1.30 1 0 0.0 0.00 1.0e+00 PPP1R14B
Allergy or Eczema 5.01 22 16 48.5 -0.51 1.3e-02 AC010733.5 AC010883.5 AC074117.10 C11orf30 CCDC116 IGHEP2 IL18R1 KIAA1109 LIME1 LRRC32 NAGLU NDFIP1 NFATC2IP PLCL1 PNMT PTGER4 RP11-373D23.3 SLC22A5 SMAD3 STMN3 UQCRQ ZBTB38
Cardiovascular Disease 1.83 7 3 9.1 -0.62 9.8e-02 AC074117.10 ADO ATG16L1 FUT2 NFATC2IP SLC22A5 STMN3
Hypothyroidism (self reported) 3.60 10 5 15.2 -0.03 9.3e-01 AC010733.5 DCLRE1B DNAJC28 FUT2 GIGYF1 NRIP1 PPP1R14B PTRF RNASET2 ZMIZ1
Respiratory disease 5.81 11 9 27.3 0.15 6.1e-01 KIAA1109 LACC1 LIME1 LRRC32 NDFIP1 P4HA2 PDLIM4 PNMT SLC22A5 SMAD3 UQCRQ
Type 2 Diabetes (T2D) 1.94 3 2 6.1 0.00 1.0e+00 AC010883.5 AC074117.10 STMN3
Lung FEV1/FVC ratio 2.21 15 9 27.3 -0.62 6.5e-03 AC010733.5 AC010883.5 ADCY3 ADO FUT2 IL18R1 P4HA2 PDLIM4 PNMT RP11-464F9.22 SLC22A5 SMAD3 TSPAN14 UQCRQ ZBTB38
Lung FVC 2.04 14 8 24.2 0.74 6.8e-04 ANKRD43 CARD9 HEATR3 HINT1 LIME1 NFATC2IP P4HA2 PARK7 PNMT RP11-464F9.22 RSPO3 SLC22A5 STMN3 ZBTB38
Neuroticism 1.09 1 1 3.0 0.00 1.0e+00 CD40
Chronotype (morning person) 1.11 1 0 0.0 0.00 1.0e+00 PLCL1
Hair Pigment 0.43 10 9 27.3 -0.55 9.8e-02 AC010883.5 AC074117.10 ADAM15 ADCY3 DOCK8 GIGYF1 MARK3 RP11-297A16.2 SYNGR1 ZBTB38
Tanning 0.24 4 3 9.1 0.97 3.4e-02 AC074117.10 ADCY3 ADO IL18R1
Hand grip strength (left) 2.05 8 6 18.2 0.78 8.0e-03 ADCY3 ANKRD43 HINT1 P4HA2 PDLIM4 RFT1 SLC22A5 ZBTB38
Number of treatments/medications taken 1.72 2 0 0.0 0.00 1.0e+00 AC074117.10 DCLRE1B
Average weekly spirits intake 1.08 2 0 0.0 0.00 1.0e+00 FUT2 MST1
Relative age of first facial hair 1.14 2 0 0.0 0.00 1.0e+00 RP11-297A16.2 ZBTB38
Systolic blood pressure, automated reading 1.09 1 1 3.0 0.00 1.0e+00 ADO
Medication: Metformin 1.79 2 1 3.0 0.00 1.0e+00 AC010883.5 AC074117.10
Diabetes (father) 1.71 1 1 3.0 0.00 1.0e+00 AC010883.5
Impedance of leg (right) 1.40 10 8 24.2 0.20 4.9e-01 AC010883.5 AC074117.10 ADCY3 CCDC116 HEATR3 HINT1 MARK3 NFATC2IP PLCL1 RP11-429P3.3
Leg fat-free mass (left) 2.33 14 9 27.3 0.63 9.0e-03 AC074117.10 ADO ANKRD43 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 PPP1R14B SLC22A5 UQCRQ ZBTB38 ZMIZ1
Trunk fat percentage 1.62 5 5 15.2 0.61 2.8e-01 ADCY3 LIME1 MST1 NFATC2IP ZBTB38
Hand grip strength (right) 2.14 9 8 24.2 0.61 3.4e-02 ADCY3 ANKRD43 HINT1 NFATC2IP P4HA2 PDLIM4 RFT1 SLC22A5 ZBTB38
Current tobacco smoking 1.30 2 2 6.1 0.00 1.0e+00 LIME1 STMN3
Fed-up feelings 1.42 2 1 3.0 0.00 1.0e+00 MST1 PPP1R14B
Taking other prescription medications 1.77 3 1 3.0 0.00 1.0e+00 DCLRE1B PPP1R14B RNASET2
Age when periods started (menarche) 1.56 2 1 3.0 0.00 1.0e+00 ADCY3 C11orf30
Heel bone mineral density (BMD) T-score, automated (left) 2.54 3 2 6.1 0.00 1.0e+00 MARK3 MST1 RSPO3
High blood pressure 1.58 5 2 6.1 0.11 8.1e-01 ADO ANKRD43 FUT2 PDLIM4 SLC22A5
Hayfever, allergic rhinitis or eczema 5.05 21 14 42.4 0.39 6.5e-02 AC010733.5 AC010883.5 AC074117.10 C11orf30 CCDC116 IGHEP2 KIAA1109 LIME1 LRRC32 NAGLU NDFIP1 P4HA2 PLCL1 PNMT PTGER4 RP11-373D23.3 SLC22A5 SMAD3 STMN3 UQCRQ ZBTB38
Medication: Levothyroxine sodium 2.84 4 2 6.1 0.26 7.4e-01 DCLRE1B GIGYF1 PTRF RNASET2
Sitting height 2.47 17 13 39.4 0.45 5.4e-02 AC074117.10 ADCY3 ADO ANKRD43 CARD9 CCDC116 FUT2 HINT1 MIER1 P4HA2 PDLIM4 PPP1R14B RFT1 RSPO3 SLC22A5 UQCRQ ZBTB38
Body mass index (BMI) 1.46 7 4 12.1 0.54 2.1e-01 ADCY3 GALC MARK3 MST1 NFATC2IP PLCL1 RFT1
Impedance of leg (left) 1.47 11 8 24.2 0.13 6.5e-01 AC010883.5 AC074117.10 ADCY3 CCDC116 FIBP HEATR3 HINT1 MARK3 NFATC2IP PLCL1 RP11-429P3.3
Leg predicted mass (left) 2.33 14 9 27.3 0.63 9.2e-03 AC074117.10 ADO ANKRD43 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 PPP1R14B SLC22A5 UQCRQ ZBTB38 ZMIZ1
Trunk fat mass 1.76 6 6 18.2 0.62 1.9e-01 ADCY3 HINT1 LIME1 MST1 NFATC2IP ZBTB38
Waist circumference 1.56 8 4 12.1 0.81 1.6e-02 ADCY3 HINT1 LIME1 MARK3 NFATC2IP RSPO3 ZBTB38 ZMIZ1
Had menopause 1.37 1 1 3.0 0.00 1.0e+00 AC074117.10
Forced vital capacity (FVC) 1.38 6 4 12.1 -0.26 6.2e-01 ADCY3 LIME1 RFT1 RSPO3 STMN3 ZBTB38
Heel bone mineral density (BMD) T-score, automated (right) 2.43 4 2 6.1 0.26 7.4e-01 MARK3 MST1 RSPO3 ZBTB38
Qualifications: None of the above 0.92 3 1 3.0 0.00 1.0e+00 MST1 NFATC2IP RFT1
Mouth/teeth dental problems 1.19 1 0 0.0 0.00 1.0e+00 FUT2
Allergy 5.94 19 14 42.4 -0.14 5.2e-01 AC010733.5 C11orf30 CCDC116 HINT1 IGHEP2 KIAA1109 LIME1 LRRC32 NDFIP1 P4HA2 PDLIM4 PLCL1 PNMT RP11-373D23.3 SLC22A5 SMAD3 STMN3 UQCRQ ZBTB38
Diabetes (self-reported) 1.85 2 2 6.1 0.00 1.0e+00 AC010883.5 AC074117.10
Hayfever/allergic rhinitis (self-reported) 2.92 6 2 6.1 0.67 1.5e-01 C11orf30 KIAA1109 LRRC32 PLCL1 PNMT SMAD3
Medication: Simvastatin 1.53 2 1 3.0 0.00 1.0e+00 AC074117.10 FUT2
Fluid intelligence score 1.27 2 1 3.0 0.00 1.0e+00 MST1 NFATC2IP
Neuroticism score 1.13 2 0 0.0 0.00 1.0e+00 AC010883.5 CD40
Weight 1.99 11 8 24.2 0.58 4.0e-02 AC074117.10 ADCY3 HINT1 LIME1 MST1 NFATC2IP P4HA2 PDE4A PPP1R14B SLC22A5 ZBTB38
Impedance of arm (right) 1.26 9 5 15.2 0.79 6.1e-03 AC074117.10 HEATR3 LRRC32 MARK3 NDFIP1 PLCL1 RFT1 RP11-373D23.3 SMAD3
Arm fat percentage (right) 1.67 6 4 12.1 0.56 2.5e-01 ADCY3 GALC LIME1 MARK3 MST1 NFATC2IP
Trunk fat-free mass 2.39 16 12 36.4 0.58 1.2e-02 AC074117.10 ADO ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 UQCRQ ZBTB38 ZMIZ1
Hip circumference 1.64 8 6 18.2 0.66 7.2e-02 ADCY3 HINT1 LIME1 NFATC2IP PDE4A PPP1R14B RSPO3 ZBTB38
Alcohol intake versus 10 years previously 1.48 3 1 3.0 0.00 1.0e+00 AC074117.10 FUT2 MST1
Father's age at death 1.60 1 0 0.0 0.00 1.0e+00 SLC22A5
Worrier / anxious feelings 1.20 1 0 0.0 0.00 1.0e+00 MTMR3
Frequency of tiredness / lethargy in last 2 weeks 1.30 1 0 0.0 0.00 1.0e+00 RP11-464F9.22
Forced expiratory volume in 1-second (FEV1) 1.41 8 3 9.1 0.40 3.3e-01 ADCY3 LIME1 PDLIM4 RFT1 RSPO3 SLC22A5 STMN3 ZBTB38
Pulse rate 1.66 3 2 6.1 0.00 1.0e+00 AC074117.10 GIGYF1 ZBTB38
Qualifications: A levels/AS levels or equivalent 1.10 1 1 3.0 0.00 1.0e+00 MST1
Mouth/teeth dental problems: Dentures 1.40 3 0 0.0 0.00 1.0e+00 ADCY3 FUT2 PNMT
Asthma 6.11 10 9 27.3 -0.22 4.7e-01 KIAA1109 LACC1 LRRC32 NDFIP1 P4HA2 PDLIM4 PNMT SLC22A5 SMAD3 UQCRQ
Medication: Cholesterol lowering 1.52 2 1 3.0 0.00 1.0e+00 AC074117.10 FUT2
Forced expiratory volume in 1-second (FEV1), Best measure 1.34 8 2 6.1 0.41 3.1e-01 ADCY3 ADO LIME1 PDLIM4 RFT1 SLC22A5 STMN3 ZBTB38
Impedance of arm (left) 1.24 8 3 9.1 0.84 4.7e-03 AC074117.10 ADCY7 HEATR3 LRRC32 MARK3 PLCL1 RP11-373D23.3 SMAD3
Arm fat mass (right) 1.67 8 6 18.2 0.63 9.6e-02 ADCY3 GALC HINT1 LIME1 MARK3 MST1 NFATC2IP ZBTB38
Trunk predicted mass 2.39 16 12 36.4 0.58 1.2e-02 AC074117.10 ADO ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 UQCRQ ZBTB38 ZMIZ1
Standing height 3.15 18 13 39.4 0.55 7.8e-03 AC074117.10 ADCY3 ADO ANKRD43 CARD9 CCDC116 FUT2 HINT1 MIER1 P4HA2 PDE4A PDLIM4 PTRF RFT1 RP11-373D23.3 SLC22A5 UQCRQ ZBTB38
Seen doctor (GP) for nerves, anxiety, tension or depression 1.28 2 0 0.0 0.00 1.0e+00 MIER1 SGIP1
Hair/balding pattern: Pattern 4 1.13 2 1 3.0 0.00 1.0e+00 AC010883.5 ZBTB38
Birth weight of first child 1.56 2 1 3.0 0.00 1.0e+00 TSPAN14 ZBTB38
Peak expiratory flow (PEF) 1.17 2 2 6.1 0.00 1.0e+00 AC010883.5 FUT2
Medication for cholesterol, blood pressure or diabetes 1.52 1 0 0.0 0.00 1.0e+00 FUT2
Gout (self-reported) 1.87 2 1 3.0 0.00 1.0e+00 AC074117.10 PPP1R14B
Hypothyroidism/myxoedema (self-reported) 3.17 7 3 9.1 -0.11 8.1e-01 DCLRE1B GIGYF1 NRIP1 PPP1R14B PTRF RNASET2 ZMIZ1
Medication: Ventolin 100micrograms inhaler 2.69 6 1 3.0 0.30 5.7e-01 KIAA1109 LRRC32 NDFIP1 PNMT SMAD3 UQCRQ
Birth weight 1.52 2 1 3.0 0.00 1.0e+00 FUT2 RFT1
Forced vital capacity (FVC), Best measure 1.19 5 5 15.2 0.18 7.7e-01 ADCY3 LIME1 RFT1 STMN3 ZBTB38
Body fat percentage 1.59 5 4 12.1 0.62 2.7e-01 ADCY3 LIME1 MST1 NFATC2IP ZBTB38
Leg fat percentage (right) 1.56 4 4 12.1 0.59 4.1e-01 ADCY3 LIME1 MST1 NFATC2IP
Arm fat-free mass (right) 2.23 13 11 33.3 0.53 4.4e-02 AC074117.10 ANKRD43 CARD9 FUT2 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38
Exposure to tobacco smoke outside home 1.71 1 0 0.0 0.00 1.0e+00 RP11-464F9.22
Comparative body size at age 10 3.12 4 2 6.1 0.54 4.6e-01 ADCY3 FUT2 NFATC2IP PLCL1
Wheeze or whistling in the chest in last year 2.15 6 4 12.1 0.23 6.6e-01 KIAA1109 LIME1 LRRC32 PNMT SLC22A5 SMAD3
Shortness of breath walking on level ground 1.28 1 0 0.0 0.00 1.0e+00 LRRC32
Qualifications: College or University degree 1.45 4 2 6.1 -0.15 8.5e-01 LIME1 MST1 NFATC2IP STMN3
Medication: Allopurinol 1.57 2 1 3.0 0.00 1.0e+00 AC074117.10 RP11-373D23.3
Medication: Seretide 50 evohaler 2.20 3 1 3.0 -0.97 2.5e-02 P4HA2 PDLIM4 SLC22A5
Mean time to correctly identify matches 0.94 1 0 0.0 0.00 1.0e+00 ADCY3
Whole body fat mass 1.69 7 6 18.2 0.62 1.4e-01 ADCY3 HINT1 LIME1 MARK3 MST1 NFATC2IP ZBTB38
Leg fat mass (right) 1.55 6 5 15.2 0.59 2.1e-01 ADCY3 HINT1 LIME1 MST1 NFATC2IP ZBTB38
Arm predicted mass (right) 2.22 14 11 33.3 0.53 3.6e-02 AC074117.10 ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 SYNGR1 ZBTB38 ZMIZ1
Pulse rate, automated reading 2.11 7 4 12.1 0.30 5.1e-01 AC074117.10 C11orf30 FUT2 GIGYF1 LIME1 MST1 ZBTB38
Alcohol intake frequency. 1.69 4 2 6.1 -0.18 7.7e-01 AC074117.10 FUT2 MST1 NFATC2IP
Comparative height size at age 10 2.79 15 13 39.4 0.64 2.9e-03 AC010883.5 AC074117.10 ADCY3 ANKRD43 CARD9 CCDC116 FUT2 HINT1 NFATC2IP P4HA2 PDLIM4 RFT1 SLC22A5 UQCRQ ZBTB38
Suffer from 'nerves' 1.24 1 1 3.0 0.00 1.0e+00 NFATC2IP
Overall health rating 1.12 2 1 3.0 0.00 1.0e+00 MST1 PLCL1
Hypertension (Self-reported) 1.51 5 3 9.1 0.06 9.0e-01 ADO ANKRD43 FUT2 PDLIM4 SLC22A5
Illnesses of father: Heart disease 1.40 1 0 0.0 0.00 1.0e+00 SMAD3
Forced expiratory volume in 1-second (FEV1), predicted 1.99 6 2 6.1 0.90 2.4e-03 P4HA2 PDE4A PDLIM4 RFT1 SLC22A5 ZBTB38
Whole body fat-free mass 2.38 16 11 33.3 0.59 9.5e-03 AC074117.10 ADO ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 UQCRQ ZBTB38 ZMIZ1
Leg fat-free mass (right) 2.29 13 9 27.3 0.73 1.8e-03 AC074117.10 ADO ANKRD43 HINT1 MARK3 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 SLC22A5 UQCRQ ZBTB38
Arm fat percentage (left) 1.64 6 4 12.1 0.55 2.5e-01 ADCY3 GALC LIME1 MARK3 MST1 NFATC2IP
Long-standing illness, disability or infirmity 1.67 2 0 0.0 0.00 1.0e+00 DCLRE1B RNASET2
Diabetes diagnosed by doctor 1.84 2 2 6.1 0.00 1.0e+00 AC010883.5 AC074117.10
Qualifications: nursing, teaching 1.01 1 0 0.0 0.00 1.0e+00 MST1
Mouth/teeth dental problems: Mouth ulcers 2.04 4 1 3.0 -0.19 8.1e-01 IL12B PNMT PPP5C TNFSF15
Medication for cholesterol 1.50 1 0 0.0 0.00 1.0e+00 FUT2
Asthma (self-reported) 6.09 12 9 27.3 -0.22 4.3e-01 HINT1 KIAA1109 LACC1 LRRC32 NDFIP1 P4HA2 PDLIM4 PNMT RP11-297A16.2 SLC22A5 SMAD3 UQCRQ
Osteoporosis (self-reported) 1.53 1 0 0.0 0.00 1.0e+00 PPP1R14B
Illnesses of father: None of the above (group 1) 1.18 1 0 0.0 0.00 1.0e+00 SMAD3
Smoking status: Current 1.23 2 0 0.0 0.00 1.0e+00 LIME1 STMN3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.21 3 2 6.1 0.00 1.0e+00 LIME1 PNMT STMN3
Whole body water mass 2.38 16 11 33.3 0.59 9.4e-03 AC074117.10 ADO ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 UQCRQ ZBTB38 ZMIZ1
Leg predicted mass (right) 2.29 13 9 27.3 0.73 1.9e-03 AC074117.10 ADO ANKRD43 HINT1 MARK3 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 SLC22A5 UQCRQ ZBTB38
Arm fat mass (left) 1.63 8 6 18.2 0.63 9.6e-02 ADCY3 GALC HINT1 LIME1 MARK3 MST1 NFATC2IP ZBTB38
Number of self-reported non-cancer illnesses 2.34 4 1 3.0 0.36 5.6e-01 AC074117.10 LRRC32 SLC22A5 STMN3
Medication: Blood pressure 1.56 2 1 3.0 -0.99 7.5e-03 P4HA2 SLC22A5
High cholesterol (Self-reported) 2.01 2 2 6.1 0.00 1.0e+00 AC074117.10 FUT2
Medication: Bendroflumethiazide 1.89 4 0 0.0 -0.97 3.2e-02 ANKRD43 P4HA2 PDLIM4 SLC22A5
Medication: Atorvastatin 1.56 1 1 3.0 0.00 1.0e+00 AC074117.10
Basal metabolic rate 2.31 16 10 30.3 0.60 8.4e-03 AC074117.10 ADO ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 UQCRQ ZBTB38 ZMIZ1
Leg fat percentage (left) 1.64 4 4 12.1 0.61 3.9e-01 ADCY3 LIME1 MST1 NFATC2IP
Arm fat-free mass (left) 2.27 13 11 33.3 0.53 4.3e-02 AC074117.10 ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Number of operations (self-reported) 1.19 1 0 0.0 0.00 1.0e+00 PARK7
Irritability 1.13 2 0 0.0 0.00 1.0e+00 AC010883.5 ERAP2
Ever had prostate specific antigen (PSA) test 1.29 1 0 0.0 0.00 1.0e+00 ZBTB38
Fractured/broken bones in last 5 years 1.39 1 1 3.0 0.00 1.0e+00 RSPO3
Diastolic blood pressure, automated reading 1.78 8 5 15.2 0.17 6.9e-01 ADO DNAJC28 ERAP2 GIGYF1 LIME1 MST1 SLC22A5 STMN3
Vascular/heart problems diagnosed by doctor 1.67 6 2 6.1 0.01 9.8e-01 ADO ANKRD43 FUT2 PDLIM4 SLC22A5 SMAD3
Cholesterol lowering medication 1.54 2 1 3.0 0.00 1.0e+00 AC074117.10 FUT2
Medication: Omeprazole (e.g. Zanprol) 1.11 1 0 0.0 0.00 1.0e+00 LIME1
Impedance of whole body 1.29 11 6 18.2 0.64 1.1e-02 AC010883.5 AC074117.10 ADCY3 HEATR3 HINT1 LRRC32 MARK3 PLCL1 RP11-373D23.3 RP11-429P3.3 ZMIZ1
Leg fat mass (left) 1.56 7 5 15.2 0.60 1.5e-01 ADCY3 HINT1 LIME1 MARK3 MST1 NFATC2IP ZBTB38
Arm predicted mass (left) 2.31 13 11 33.3 0.53 4.2e-02 AC074117.10 ANKRD43 CARD9 HINT1 NFATC2IP P4HA2 PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 26 0.746 2.17
GTEx Adipose Visceral Omentum 15 0.737 2.20
GTEx Adrenal Gland 11 0.757 2.15
GTEx Artery Aorta 23 0.773 2.15
GTEx Artery Coronary 14 1.185 2.22
GTEx Artery Tibial 37 0.985 2.25
GTEx Brain Caudate basal ganglia 13 1.410 2.33
GTEx Brain Cerebellar Hemisphere 18 1.208 2.40
GTEx Brain Cerebellum 21 1.059 2.32
GTEx Brain Cortex 12 1.159 2.38
GTEx Brain Frontal Cortex BA9 7 0.757 2.20
GTEx Brain Hippocampus 5 0.954 2.20
GTEx Brain Hypothalamus 6 1.017 2.40
GTEx Brain Nucleus accumbens basal ganglia 12 1.386 2.27
GTEx Brain Putamen basal ganglia 7 1.120 2.42
GTEx Breast Mammary Tissue 17 0.863 2.12
GTEx Breast Mammary Tissue (Male) 12 1.007 2.15
GTEx Breast Mammary Tissue (Female) 11 0.671 2.13
GTEx Cells EBV-transformed lymphocytes 9 0.633 2.13
GTEx Cells Transformed fibroblasts 36 0.858 2.19
GTEx Colon Sigmoid 12 0.822 2.19
GTEx Colon Transverse 22 1.067 2.21
GTEx Esophagus Gastroesophageal Junction 22 1.522 2.34
GTEx Esophagus Mucosa 38 1.145 2.54
GTEx Esophagus Muscularis 29 0.899 2.18
GTEx Heart Atrial Appendage 18 1.141 2.43
GTEx Heart Left Ventricle 12 0.784 2.18
GTEx Liver 3 0.420 2.13
GTEx Lung 36 1.256 2.40
GTEx Muscle Skeletal 24 0.832 2.16
GTEx Nerve Tibial 44 1.019 2.24
GTEx Ovary 13 1.429 2.55
GTEx Pancreas 10 0.613 2.06
GTEx Pituitary 12 1.077 2.32
GTEx Prostate 10 1.203 2.50
GTEx Skin Not Sun Exposed Suprapubic 29 1.182 2.41
GTEx Skin Sun Exposed Lower leg 30 0.826 2.27
GTEx Small Intestine Terminal Ileum 4 0.875 2.07
GTEx Spleen 16 1.136 2.47
GTEx Stomach 15 1.032 2.35
GTEx Testis 28 0.888 2.19
GTEx Thyroid 35 0.877 2.23
GTEx Uterus 5 0.883 2.27
GTEx Vagina 8 1.260 2.43
GTEx Whole Blood 26 1.305 2.75
METSIM Adipose 45 0.977 2.19
NTR Blood 33 1.373 2.62
ROSMAP Brain Pre-frontal Cortex 32 0.729 2.00
YFS Blood 42 0.909 2.26
CommonMind Brain Pre-frontal Cortex 39 0.726 2.01
TCGA Breast Tumor 6 0.783 2.27
TCGA Breast Normal 23 0.547 1.92
TCGA Ovarian Tumor 15 0.514 1.81
TCGA Prostate Tumor 34 0.983 2.12